Last reviewed · How we verify

Kalcipos-D — Competitive Intelligence Brief

Kalcipos-D (Kalcipos-D) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D analog with calcium supplement. Area: Endocrinology / Bone Metabolism.

marketed Vitamin D analog with calcium supplement Vitamin D receptor (VDR) Endocrinology / Bone Metabolism Small molecule Live · refreshed every 30 min

Target snapshot

Kalcipos-D (Kalcipos-D) — Takeda. Kalcipos-D combines calcipotriol (a vitamin D analog) with calcium carbonate to regulate calcium and phosphate metabolism and promote bone mineralization.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Kalcipos-D TARGET Kalcipos-D Takeda marketed Vitamin D analog with calcium supplement Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D analog with calcium supplement class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kalcipos-D — Competitive Intelligence Brief. https://druglandscape.com/ci/kalcipos-d. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: